Mink Therapeutics Inc logo

Mink Therapeutics Inc(INKT)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$9.34
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for INKT

11/13/2026: INKT (1-star) is currently NOT-A-BUY. Pass it for now.

Mink Therapeutics Inc is a clinical-stage biotechnology stock focused on pioneering allogeneic invariant natural killer T cell therapies for cancer and immune diseases. The company's primary strength lies in its proprietary platform and lead candidate agenT-797, which offers unique tissue-homing properties currently evaluated in Phase 2 clinical trials. Its main growth opportunity centers on positive clinical data readouts and potential biopharmaceutical partnerships. However, the company faces substantial execution, funding, and clinical trial risks, alongside a history of net losses and share dilution. The stock suits high-risk growth and momentum investors willing to monitor clinical milestones and cash runway developments closely.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitThe company offers high-risk clinical upside potential, but lacks predictable revenue growth.
Momentum investorStrong fit while signal remains positivePositive clinical trial catalysts or partnership announcements can drive sharp short-term trading momentum.
Value investorWeak fitThe lack of earnings, positive cash flow, and book-value stability make it unsuitable for traditional value strategies.
Dividend investorWeak fitThe company pays no dividends and retains all capital for clinical trials.
Low-risk investorWeak fitHigh clinical uncertainty, volatility, and capital-dilution risks create a high-risk profile.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighMicro-cap biotech shares experience sharp price swings driven by clinical trial updates and market sentiment.
Valuation riskHighValuation is speculative and heavily dependent on future clinical milestones rather than current fundamentals.
Competition risk (cell therapy development)Medium / highThe company competes with numerous well-funded entities pursuing alternative oncology and immunology treatments.
Business qualityMediumWhile pioneering a unique iNKT platform, the business model remains pre-commercial and dependent on external financing.
Dividend incomeLow / noneNo dividend is paid or anticipated in the foreseeable future.
Execution riskHighSuccessful clinical trial completion and regulatory clearance are mandatory for long-term viability.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 47.95M USD
Price to earnings Ratio -
1Y Target Price 44
Price to earnings Ratio -
1Y Target Price 44
Volume (30-day avg) 13.3K shares
Beta 0.45
52 Weeks Range 8.48 - 16.93
Updated Date 11/15/2026
52 Weeks Range 8.48 - 16.93
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -2.23

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Rolling Over
PRICE PATH

Rolling Over

The price momentum is slowing down and beginning to turn downward.

Highly Choppy
PRICE STABILITY

Highly Choppy

The stock has experienced frequent, large price swings that make its near-term movement less predictable.

Analysis of Past Performance

Type Stock
Historic Profit -84.2%
Avg. Invested days 11
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
INKT receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
INKT has moderate overall fundamentals (3 stars), with moderate financial health, moderate growth momentum, and moderate ownership. In FY2025 versus FY2024, growth and ownership metrics are mixed: negative earnings growth (-15.9%), soft cash generation (FCF margin 0.0%), slightly negative revenue growth (+0.0%).

Financial Health Rating

★★★★★
INKT's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Free-cash-flow growth is INKT's strongest growth driver at +38.0% FY2025 versus FY2024 (strong, 5 stars). By comparison, while revenue growth (+0.0%, slightly negative) and earnings growth (-15.9%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 4.1% (soft) and 40.4% of outstanding shares are publicly tradable (moderate). Insider ownership of 59.35% supports management-shareholder alignment.

Top 5 Institutional Investors

Vanguard Capital Management, LLC 1.35%
DnB NOR Asset Management (Asia) 1.08%
Longbow Finance SA 0.33%
Geode Capital Management, LLC 0.31%
Citadel Advisors Llc 0.30%

Unit Economics (Per $1K Revenue)

★★★★★
INKT generates approximately $-0 of gross profit, $-0 of operating income, and $-0 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Weak margins explain the 1-star rating, with weak cash conversion and strong capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
INKT has a relatively low-volatility profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap Risk

How Company Makes Money

Business areaWhat it includesRetail investor read
Therapeutic Development and Pre-Commercial Program AccessEarly-stage grant funding, collaborative research arrangements, and nominal specialized access program revenues.The company does not yet sell commercial drugs at scale and relies primarily on capital markets and grants to fund operations.

Valuation

Trailing PE -
Forward PE -
Enterprise Value 39.77M
Price to Sales(TTM) 239.74
Enterprise Value 39.77M
Price to Sales(TTM) 239.74
Enterprise Value to Revenue 198.84
Enterprise Value to EBITDA -3.67
Shares Outstanding 5.13M
Shares Floating 2.07M
Shares Outstanding 5.13M
Shares Floating 2.07M
Percent Insiders 59.35
Percent Institutions 4.08

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.